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Background: The NHS Cancer Drugs Fund (CDF) was established in 2010 to reduce delays and improve access to cancer drugs,
including those that had been previously appraised but not approved by NICE (National Institute for Health and Care
Excellence). After 1.3 billion GBP expenditure, a UK parliamentary review in 2016 rationalized the CDF back into NICE.
Methods: This paper analyses the potential value delivered by the CDF according to six value criteria. This includes validated
clinical benefits scales, cost-effectiveness criteria as defined by NICE and an assessment of real-world data. The analysis focuses
on 29 cancer drugs approved for 47 indications that could be prescribed through the CDF in January 2015.
Results: Of the 47 CDF approved indications, only 18 (38%) reported a statistically significant OS benefit, with an overall median
survival of 3.1months (1.4–15.7months). When assessed according to clinical benefit scales, only 23 (48%) and 9 (18%) of the 47
drug indications met ASCO and ESMO criteria, respectively. NICE had previously rejected 26 (55%) of the CDF approved
indications because they did not meet cost-effectiveness thresholds. Four drugs—bevacizumab, cetuximab, everolimus and
lapatinib—represented the bulk of CDF applications and were approved for a total of 18 separate indications. Thirteen of these
indications were subsequently delisted by the CDF in January 2015 due to insufficient evidence for clinical benefit—data which
were unchanged since their initial approval.
Conclusions: We conclude the CDF has not delivered meaningful value to patients or society. There is no empirical evidence
to support a ‘drug only’ ring fenced cancer fund relative to concomitant investments in other cancer domains such as surgery
and radiotherapy, or other noncancer medicines. Reimbursement decisions for all drugs and interventions within cancer care
should be made through appropriate health technology appraisal processes.
Key words: cancer economics, health policy, clinical beneﬁt scales, patient access schemes, health technology assessment
Introduction
The Cancer Drugs Fund (CDF) was established in 2010 by the
UK government to provide patients with access to cancer drugs
not available through the NHS, because the drugs had not been
appraised, were in the process of being appraised, or had been
appraised but not recommended by the National Institute of
Health and Care Excellence (NICE). As well as reducing delays
and improving access to cancer drugs within the NHS it also
offered an opportunity to provide funding for orphan indica-
tions or rare conditions that NICE would ordinarily not ap-
praise [1].
The CDF had an initial budget of £50 million per annum with
the plan to move towards a value-based pricing scheme by 2014.
However, the costs of maintaining the fund rapidly increased,
with the budget set at £200 million in 2013/2014, £280 million in
2014/2015, and £340 million in 2015/2016. At the time of its uni-
fication with NICE (see Figure 1), the CDF had cost of UK
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taxpayer a total of £1.27 billion [2], the equivalent of 1 year’s total
spend on all cancer drugs in the NHS [3].
Despite an extensive public consultation, fundamental issues
about whether the CDF was a beneficial and fair public policy de-
cision that actually delivered value have been absent from the dis-
course. Such analysis is essential to inform pharmaceutical policy
in other countries contemplating such patient access pathways
for high-cost cancer drugs.
Methods
In this policy analysis, we review the utility of such patient access
funds for pharmaceutical agents by assessing the value delivered
to both individuals and society by the CDF. Six value criteria have
been used in our analysis. This includes an assessment of:
1. The index trial data that provided the evidence for the drugs’
efﬁcacy
2. Observational studies assessing the effectiveness of selected
CDF approved drugs in ‘real world’ populations
3. The value of approved drugs according to validated clinical
beneﬁt scales developed by The American Society of Clinical
Oncology (ASCO) and The European Society for Medical
Oncology (ESMO)
4. Whether the drugs would meet cost-effectiveness thresholds
set by NICE
5. The CDF committee’s own review (in January and
November 2015) of drugs they had approved
6. The value delivered by CDF-approved drugs to NHS patients
based on utilization patterns
These criteria were chosen as they provide a multi-dimensional
approach to assessing value in the absence of clinical data on out-
comes for patients receiving drugs through the CDF. The first
measures clinical efficacy based on the index clinical trial data,
and the second, the translation of trial efficacy to a real world
population in light of the socio-demographic make-up of trial
participants. The third criteria goes beyond a simple evaluation
of absolute study end-points to assess meaningful benefit accord-
ing to value scales developed by two professional bodies, ASCO
and ESMO.
The fourth looks at the issue of distributive justice by assessing
cost-effectiveness according to health technology assessment
frameworks, in this case NICE. The fifth criteria, represents an
evaluation of the CDF committee’s own audit of each of the
approved drugs and indications using their own value framework
undertaken in January and November 2015. The sixth and final
criteria collates the evidence for value based on patterns of use of
CDF drugs (dose, volume) where data is available and the likely
benefits that have been derived when considering the index trial
data.
We focus on the systemic therapies that were made available
and could be prescribed through the CDF prior to the January
2015 update when the fund was first rationalized [4]. Up to this
point, 29 drugs had been approved for 47 indications, three of
which—bevacizumab (9), cetuximab (4), and everolimus (3)—
had been approved for more than two indications.
Results
Did sufficient clinical evidence exist to suggest
patients would benefit from CDF approved drugs?
On review of the index trial data for the 47 drug indications
approved by the CDF [5–53], only 18 (38%) reported a statistic-
ally significant overall survival (OS) benefit (Table 1) [5–7, 9, 13,
14, 18, 20, 23, 26, 27, 38, 41, 44, 45, 47, 50, 51] The median OS
benefit was 3.2months, ranging from 1.4months (hazard ratio
0.82) for aflibercept in metastatic bowel cancer [6] to
15.7months (HR 0.68) for pertuzumab in first line metastatic
Her-2 positive breast cancer [44].
Of the remaining 29 indications in the CDF, 17 were approved
despite no statistically significant OS benefit being observed in
the index trials. These included axitinib [8] bevacizumab (five in-
dications) [10–12, 16, 17], cabozantinib [19], cetuximab (two in-
dications) [21, 22], everolimus (four indications) [29–32],
lapatinib [35], panitumimab [36], pazopanib [39], and peme-
trexed [42]. The primary end-point of 14 of these studies was
PFS, of which five allowed cross-over of the control population at
progression to the intervention arm [30–32, 35, 36] and one had
significant post-study utilization (49.6%) of the intervention
drug among the control arm [22].
12 further indications had been approved without OS data
being available. The primary end-point in the index trial for eight
Following a three-month consultation between November 2015 
and February 2016 the Cancer Drugs Fund (CDF) moved to a 
new operating procedure that resulted in it becoming closely 
aligned with NICE. 
Drugs available through the CDF that had been previously 
appraised by NICE and rejected, were no longer to be funded 
unless the manufacturers were able to provide new evidence or 
to change the terms of reimbursement to support its routine 
commissioning. As an example abiraterone, cabazitaxel and 
enzalutamide were all approved for the treatment of advanced 
prostate cancer from Feb 2016.  
In July 2016 the CDF became a managed access fund providing 
access to new cancer drugs for a time limited period (expected to 
be no more than 2 years) in circumstances where the clinical and 
cost effectiveness of the drug is deemed uncertain by NICE.  
The NICE appraisal process will now also start much earlier, 
publishing draft guidance prior to a drug receiving its marketing 
authorisation and then final guidance within 90 days of marketing 
authorisation. https://www.england.nhs.uk/wp-
content/uploads/2013/04/cdf-sop.pdf
Figure 1. Current status of the CDF Nov 2016.
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of these indications was PFS [15, 24, 25, 33, 36, 46, 48, 49, 52] of
which five allowed cross-over of the control population at pro-
gression [24, 25, 46, 48, 52]. The other four indications were not
able to report any PFS or OS benefit as they were based on
noncomparator studies [40, 43, 53].
Given that over half of the drug indications (n¼ 29) approved
by the CDF lacked any OS benefit, it is valid to ask whether a
gain in PFS is a meaningful surrogate endpoint for OS.While we
acknowledge this is a subject of much debate as there are differ-
ences of opinion as to what constitutes benefit, there is unanim-
ity that prolongation of OS is an unequivocal benefit and
desired [54–57]. From a patient’s perspective, a gain in PFS may
not equate to a clinical benefit given the serious toxicities that
arise from many of these therapies, including those classified as
‘targeted’ and the fact that progression often occurs without any
symptoms such that delaying progression is not delaying symp-
toms [58].
Furthermore, the extent to which benefits claimed in clinical
trials are true can be debated. For end-points such as OS and PFS,
it is expected that all patients randomized at the start of the study
are followed up until either the end point is reached or the study
is completed (intention-to-treat analysis). If a patient is censored
prior to the end point being reached, their outcome is estimated
based on other patients in the same arm who have not reached
the end point, but have been under longer follow-up. This will re-
sult in an over-estimation of benefit if their reason for being cen-
sored is linked to their prognosis, i.e. toxicity, low participation
in follow-up, or the initiation of an alternative therapy [59]. This
type of censoring is more common in the assessment of PFS com-
pared with OS where censoring predominantly occurs as a result
of a death [60].
In PFS analyses, censoring is often driven by drug toxicity and
the extent of censoring as regards PFS has been increasing in
many trials (disproportionately so in the experimental arm) ren-
dering the results questionable as to the true benefit observed [61,
62]. Several of the indications for drug funding on the CDF were
based on trials in which excessive censoring was a feature [19, 28,
30]. For everolimus plus exemestane in breast cancer, the
4.4months difference in OS was not significant although the PFS
difference of 4.6months was highly significant albeit in the set-
ting of excessive censoring in the everolimus arm due to toxicity
[28, 62].
Could the reported clinical trial benefits be
realized in the ‘real world’?
Randomized control trials (RCTs), have strong internal validity
through randomization, pre-specified end points and blinding,
however their external validity is limited [63]. This is because pa-
tients similar to those frequently encountered in a clinical prac-
tice are often excluded, raising questions as to the generalizability
of clinical trial results to populations, settings or conditions not
reflected in the trial [64, 65].
For example, the median age of study participants in the index
trials of CDF approved drugs was 60 (Table 1). Over 90% of the
study populations had an Eastern cooperative oncology group
(ECOG) performance status score of 0 or 1 (or equivalent) in the
majority of the trials. The under-representation of men and women
over 65 in RCTs is a long-standing issue [66, 67]. As a result, deci-
sion-makers are expressing interest in ‘real world data’ [68].
In metastatic renal cell carcinoma (mRCC), data from the ‘real
world’ provide a sobering assessment of outcomes. The
International Metastatic Renal Cell Carcinoma Database consor-
tium study found that the 35% of patients that did not meet trial
eligibility criteria had a disappointing 12.3months survival com-
pared with 28.4months survival in those that would have been
deemed trial-eligible [69]. A recent study that analysed the SEER
18 (Surveillance, Epidemiology and End Results) registry data-
base to calculate the relative survival rates for advanced RCC pa-
tients during 2001–2005, 2006–2007 and 2008–2009 concluded
there was no significant improvement in relative survival rates
among patients withmRCC in the era of targeted agents [70].
Increased rates of toxicity are also observed in real world popu-
lations. A US SEER database study evaluated the effectiveness of
adding bevacizumab to first-line combination chemotherapy for
Medicare patients (aged 65 years and over) with metastatic colo-
rectal cancer (mCRC) [71]. The data showed unequivocally there
was no benefit to adding bevacizumab to FOLFOX-based regi-
mens in this Medicare population, but importantly the addition
of bevacizumab increased the risk of stroke (4.9% versus 2.5%,
respectively; P<0.01) and GI perforation (2.3% versus 1.0%, re-
spectively; P<0.01).
From a clinical standpoint would oncologists
consider the predicted benefits of the CDF
approved drugs to be clinically meaningful?
In many cases, the answer appears to be no. In 2014, The
American Society of Clinical Oncology (ASCO) published what it
considered meaningful clinical benefit in the hopes the design of
future clinical trials would produce results that would be valuable
for patients, i.e. meaningful improvements in survival, quality of
life or both [72]. The ASCO Cancer Research Committee (CRC)
that developed the criteria deliberately chose modest threshold to
ensure their relevance and attainability. OS was chosen as the pri-
mary clinical end-point of interest and minimum gains in sur-
vival and HR thresholds were defined for each tumour type,
virtually all in the metastatic setting. Secondary end-points
included PFS, and thresholds for OS and PFS were adjusted de-
pending on the toxicity profile of the drug.
An analysis of drugs approved by the FDA between 2002 and
2014 for the treatment of solid tumours found that only 42% of
the 71 approved drugs met the ASCO or comparable standards
[73]. Similarly, only 23 (48%) of the 47 CDF approved drug indi-
cations met the very modest ASCO criteria with uncertainty re-
garding six drug indications (see Table 1).
In 2015, The European Society for Medical Oncology (ESMO),
produced further guidelines (following consultation with over
250 of its expert membership) to stipulate the boundaries for
meaningful clinical benefit [74]. The scoring scheme was based
on:
• Treatment intent (curative versus noncurative)
• Expected duration of PFS and OS in the control arm
• PFS or OS beneﬁt including the hazard ratios
• Evidence of improved or worsening toxicity proﬁles
• Evidence for improvement in quality of life
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Cancer drugs indicated in the noncurative setting are scored 1
(lowest) to 5 (highest), and those in the curative setting are
graded A (highest) or B (lowest). Drugs scoring 4, 5 or A are con-
sidered to provide a high level of proven clinical benefit according
to the criteria. Our analysis of the 47 drug indications on the CDF
found that only 9 (18%) indications achieved scores of 4, 5 or A,
(see Table 1) while 23 (50%) of drug indications scored 2 or less
on the ESMO scale, i.e. they were based on study data which had
demonstrated limited evidence of clinical benefit. The nine indi-
cations that met ESMO criteria for meaningful clinical benefit
included, cetuximab for colorectal cancer [23], crizotinib for
lung cancer [24], dabrafenib for metastatic melanoma [25], ima-
tinib as adjuvant therapy for GIST [33], pertuzumab and trastu-
zumab emtansine for breast cancer [44, 51], temsirolimus for
renal cell cancer [50], radium 223 for prostate cancer [45] and
pegylated doxorubicin for sarcoma [40].
Would an HTA body, in this instance NICE, consider
the benefits of drugs on CDF of sufficient value to
be reimbursed?
In the UK, NICE is responsible for ensuring rational and fair deci-
sions are made on resource allocations by performing cost effect-
iveness analyses for new health interventions. The advantage of
the cost per QALY is its universality when making decisions re-
garding the entire spectrum of health care interventions across all
specialities [75]. NICE focus on both short and long-term out-
comes of treatment and direct patient benefits [76].
We found that 26 (55%) CDF approved drugs had previously
been rejected by NICE on the grounds of not meeting cost effect-
iveness criteria. Three (dabrafenib, imatinib and radium 223)
were due to receive approval in early 2015 (Table 1). Seven were
awaiting appraisal but draft consultation advice had been issued.
Eleven indications had not been appraised and no plans for their
assessment were evident. In some cases, this was due to the rarity
of the disease (e.g. regorafenib, in soft tissue sarcoma) or their
off-label use (bevacizumab third line in paediatric low-grade
glioma).
What the CDF committee considered the value of
CDF approved drugs to be?
The CDF committee undertook detailed assessment of each of
the drugs listed in its access scheme in January and November
2015 using a bespoke framework to assess its value. This included,
but was not limited to, PFS, OS, quality of life, toxicity, unmet
need and cost [77]. In total, 24 indications (51% of all indica-
tions) for 14 drugs were removed from the CDF list following this
appraisal, of which six were later reinstated.
Table 2 summarizes details about four drugs whose value to
the NHS can be debated: bevacizumab, lapatinib, cetuximab, and
everolimus. These four drugs were approved by the CDF for 18
separate indications—bevacizumab (9), cetuximab (4), everoli-
mus (4) and lapatinib (1). Following the initial review of the CDF
in January 2015, nine of these indications were delisted. A further
four indications were delisted in November 2015, following a
subsequent review. The value delivered by bevacizumab in par-
ticular is debatable given that six of the nine indications were de-
listed. Only one of these indications would have met ASCO
criteria and none would have achieved the ESMO meaningful
clinical benefit criteria, or NICE cost-effective thresholds.
In this respect, the criteria and value judgements initially used
by the CDF has been criticized for its lack of rigour and relevance
for prioritizing drugs for reimbursement through the fund [78].
The tabulation also underscores the fluid nature of the CDF and
raises questions as to whether approvals were occurring too
quickly or are being driven by factors other than academic/scien-
tific considerations.
Is there any evidence that the CDF has been of
value to NHS cancer patients?
At the time of commencement in 2010, it was expected that basic
outcome data would be collected from April 2012 including the
date of treatment cessation, side effects observed, 30-day mortal-
ity and date of death/next relapse. However, even after audit data
collection became mandatory in 2014, 93% of outcome data was
incomplete for 2014–2015 [79].
We therefore have no evidence as to whether recipients of
drugs from the CDF derived any meaningful benefit in terms of
survival, improved quality of life or decreased episodes of tox-
icity. As a proxy, we have attempted to define the value achieved
by NHS cancer patients receiving cancer drugs through the CDF
by assessing actual patterns of drug utilization, in conjunction
with their anticipated benefits according to the original trial data.
Stephens and Thomson in 2012 [80] using IMS health dispens-
ing data demonstrated that between April and December 2011,
59% of CDF applications were for five drugs: bevacizumab, lapa-
tinib, sorafenib, cetuximab, and everolimus; a prescribing pattern
confirmed by Chamberlain et al. in a subsequent analysis examin-
ing the period from October 2007 to October 2012 [81]. No data
on the volume of drugs utilized has since been made available,
nor information on patient weight or number of cycles com-
pleted by each patient.
The study reported that following the introduction of the CDF
there were statistically significant increases in utilization of beva-
cizumab (2-fold), and lapatinib (3-fold), and these together with
sorafenib, cetuximab, and sunitinib constituted a significant pro-
portion of drug prescriptions. The exact indication for which
these drugs were prescribed remains unknown. Analysis of the
volume data found that the growth in drug utilization was lower
than expected when compared with the doses and duration of
treatment received by patients enrolled in the original RCTs. This
is therefore likely to reflect earlier disease progression, or the oc-
currence of intolerable adverse events, suggesting their clinical ef-
fectiveness and tolerability do not match results in the RCTs [82].
In addition, there was evidence of inequitable access to the fund
across English regions (2010–2013) and according to age and sex
[79, 83].
This then raises concerns that the ‘real benefits’ in fact are not
benefits at all since they would never have achieved statistical val-
idity in a RCT or if they did, may not have been of sufficient mag-
nitude to warrant the added toxicity that invariably occurs.
Keeping inmind themedian OS benefit of CDF-approved indica-
tions was 3.1months can we be sure that 1month less than this
would be statistically better or better enough to favourably tip the
risks to benefits scale?
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Discussion and policy recommendations
Because some argued that UK lagged behind otherWestern coun-
tries in delivering therapies to cancer patients and this could lead
to disparity in outcomes, the CDF was established to ensure ac-
cess to drugs available in other countries [84]. In this respect, the
CDF has delivered its intended aims. However, we would argue
from this analysis that the CDF has not provided meaningful
value to cancer patients and wider society because the supporting
data has been wanting.
The majority of CDF-approved indications have been based on
studies that reported minimal to no benefit in survival. Other en-
dorsements have relied on surrogate endpoints such as PFS that
remain controversial given inherent flaws in trial design and the
increasing abuse of censoring. The thresholds for meaningful
clinical benefit proposed by ASCO or ESMO support our argu-
ment since the majority of CDF-approved indications were un-
able tomeet these modest levels of efficacy (Table 1).
Patients would find many of the approved indications wanting
as regards actual benefit, even before considering the burden of
the associated toxicities [85]. Current evidence suggests the ma-
jority of cancer patients with a life expectancy4months prefer
treatment that relieves pain and discomfort rather than extending
life [86] and that they expect a minimum survival benefit of
3months in this setting and potentially longer if the therapy is
associated with more severe side effects [87, 88].
We must also consider the welfare loss to society from the CDF
after expenditure of over one billion pounds [79]. An impact
equality assessment of the CDF has been undertaken for patients
receiving cancer drugs through the CDF in 2013/2014
(n¼ 19 560)[79]. It reported that the potential benefit of the
CDF to cancer patients, estimated at 3500 QALYS, has resulted in
overall net harm to population health when one considers the
health opportunity costs, with nearly 18 000 QALYS being dis-
placed from patients elsewhere in the NHS [89, 90]. It is import-
ant therefore, to tread with caution when arguments are
forwarded that all cancer drugs offering meaningful clinical bene-
fit should be funded irrespective of price, without considering
issues of value, distributive justice, and fairness. In the NHS, wait-
ing times for diagnostic interventions and elective procedures
continue to rise, many of which are directly affecting cancer pa-
tients [91].
At its inception, critics argued that the introduction of the
CDF would reduce the negotiating power of the NHS, specifically
the ability to negotiate fair prices of cancer drugs with pharma-
ceutical companies [81]. This is no more evident than when one
considers the reversals of six indications delisted in January 2015
(see Table 3). None of the reinstated indications meet the criteria
for clinical benefit according to the ESMO scale. However, nego-
tiations were prompted by the threat of the drug being delisted,
suggesting that the creation of a ring fenced access fund for cancer
drugs provides a negative incentive for drug price negotiation.
This is especially pertinent given recent evidence that the price of
drugs is based on what the market will bear as opposed to the level
of its clinical benefit [92]. Cabazitaxel, eribulin, and everolimus
(for breast cancer) have all since been approved by NICE as a re-
sult of discounts being applied by pharmaceutical companies
through the patient access scheme [93–95].
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Given the evidence set forth, decisions regarding access appear
politically motivated. The CDF was created following intense
public and political pressure to provide access no matter what the
cost or the evidence for their benefit. There was no stated estima-
tion of the ‘number of lives that could be saved’, nor, more realis-
tically, of the number of lives that may be extended. This was a
debate played out in the media, limiting the role of NICE as the
final arbiter for deciding what constitutes optimal value for soci-
ety [82]. However, 6 years later, and after considerable expend-
iture we are now reverting to a pre-existing format, namely an
independent health technology appraisal service (i.e. NICE) pro-
viding recommendations for NHS commissioning (see Figure 1).
Indeed, the evidence used by the CDF committee to re-
appraise the value of drugs in January 2015 was in most cases
available prior to the approval process, especially in circum-
stances where NICE had already undertaken an HTA appraisal.
Of the 17 indications delisted in January 2015, 13 were for indica-
tions that were previously deemed not cost-effective by NICE
(Table 1). A further seven indications were delisted in November
2015 of which five had been rejected following NICE appraisal.
While these reversals may seem innocent, if a drug approved for
an indication is subsequently deemed of insufficient value as data
become available and its benefit is questioned we must acknow-
ledge that it has then been given to patients who may have
endured toxicity without any benefit.
Finally, while the stated goal of the CDF was to ‘empower clin-
icians, and to enable them to use the cancer drugs that they and
their patients agree are needed to extend or improve life’, it is rea-
sonable to ask why so many clearly ineffective drugs were pre-
scribed in the first place. The issues are complex and cannot be
answered without in-depth qualitative research. However, two
factors may be important. The first is the so-called ‘moral haz-
ard’. When patients and providers are shielded from the costs
associated with an intervention (through insurance per se), they
will be more willing to accept/deliver health care interventions
even if the benefits are marginal [96]. Second, decision-making in
the context of illness has been shown to be prone to biases result-
ing in an over-estimation of the level of risk of disease or potential
benefits of treatment [97, 98].
Future options
One lesson from this costly saga is the need to strengthen regula-
tory and reimbursement processes and ensure they remain free
from political interference. The use of clinically meaningful benefit
thresholds such as that proposed by ASCO and ESMO seems enor-
mously prudent. The ASCOmetric in effect calls for minimumOS
gains of 2.5–4.5months or 25–50% gain over existing time scales
and the ESMO threshold essentially prioritizes gains in survival
(> 3months with hazard ratios< 0.65), quality of life and reduc-
tion in toxicity compared with current standards of care.
We would suggest other countries considering a patient access
scheme for drugs awaiting formal health technology appraisal use
value frameworks that determine the likely benefit from reim-
bursement as part of the appraisal process. If drugs are made
available pending an appraisal process, this should be accompa-
nied by rigorous collection of outcome data through coverage
with evidence development schemes. However, they should not
replace assessment of the overall cost-effectiveness, which seeks
to ascertain the societal benefit gained from drug reimbursements
relative to other health technologies across the disease spectrum.
Improvements on the current system could also be achieved
through new payment systems based on the attainment of pre-
determined outcomes [99–101] or the introduction of value-
based co-payments [102]. Another option would be to link HTA
appraisal of the benefits and costs of new drugs with national re-
bate agreements [89]. The rebate would cover the difference be-
tween the manufacturers intended price of the drug and how
much the NHS can afford to pay for its intended benefits. This
would highlight to pharmaceutical companies of the price the
NHS is willing to pay for the benefits offered by a new drug.
Companies charging high prices for drugs with limited efficacy,
would be expected to pay higher rebates. This would encourage
research funders to support cancer clinical trials whose design
and end points genuinely look for therapeutic advances that de-
liver meaningful clinical benefit rather than a low bar for
response.
Conclusions
Despite significant expenditure, there remains no evidence that
the CDF has delivered meaningful value to NHS cancer patients.
We have analysed the value of CDF approved drugs according to
six criteria including validated clinical benefit scales, and health
technology appraisal from organizations such as NICE. From
this, it is clear that the decision-making tools used by the CDF for
prioritization of new drugs have failed given that a number of
drugs were approved and subsequently delisted based on evi-
dence that previously existed.
We recommend the avoidance of similar ‘ring-fenced’ drug ac-
cess funds in other countries. The lack of empirical evidence that
prioritizing drug expenditure (the greatest cancer care costs after
inpatient care) will improve outcomes for cancer patients over
and above greater investment in the whole cancer management
pathway (screening, diagnostics, radiotherapy, surgery) and
reducing access barriers (e.g. co-payments) argue against its
widespread adoption. Ultimately, what is most important is that
reimbursement decisions for all drugs, procedures and interven-
tions within cancer care are made through appropriate health
technology appraisal processes, which use the best available evi-
dence to ensure decisions maximize value for cancer patients and
society as a whole.
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